Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction
- PMID: 20196861
- PMCID: PMC2843680
- DOI: 10.1186/1749-8090-5-9
Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction
Abstract
This the case of a 63 year-old man with end-stage renal disease (on chronic hemodialysis), unstable angina and significantly impaired myocardial contractility with low left ventricular ejection fraction, who underwent off-pump one vessel coronary bypass surgery. Combined continuous levosimendan and norepinephrine infusion (at 0.07 microg/kg/min and 0.05 microg/kg/min respectively) started immediately after anesthesia induction and continued for 24 hours. The levosimendan/norepinephrine combination helped maintain an appropriate hemodynamic profile, thereby contributing to uneventful completion of surgery and postoperative hemodynamic stability. Although levosimendan is considered contraindicated in ESRD patients, this case report suggests that combined perioperative levosimendan/norepinephrine administration can be useful in carefully selected hemodialysis patients with impaired myocardial contractility and ongoing myocardial ischemia, who undergo off-pump myocardial revascularization surgery.
Similar articles
-
Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: Single-centered randomized prospective study.Ann Card Anaesth. 2018 Apr-Jun;21(2):123-128. doi: 10.4103/aca.ACA_178_17. Ann Card Anaesth. 2018. PMID: 29652271 Free PMC article. Clinical Trial.
-
Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function.Ann Thorac Surg. 2009 Feb;87(2):448-54. doi: 10.1016/j.athoracsur.2008.10.029. Ann Thorac Surg. 2009. PMID: 19161758 Clinical Trial.
-
Levosimendan Use Increases Cardiac Performance after Coronary Artery Bypass Grafting in End-Stage Renal Disease Patients.Heart Surg Forum. 2016 Oct 27;19(5):E230-E236. doi: 10.1532/hsf.1426. Heart Surg Forum. 2016. PMID: 27801303
-
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.Surg Today. 2009;39(5):381-6. doi: 10.1007/s00595-008-3869-5. Epub 2009 Apr 30. Surg Today. 2009. PMID: 19408074 Review.
-
Levosimendan use in several scenarios of acute heart failure.Arq Bras Cardiol. 2008 Mar;90(3):211-5. doi: 10.1590/s0066-782x2008000300012. Arq Bras Cardiol. 2008. PMID: 18392402 Review. English, Portuguese.
Cited by
-
Levosimendan in critical illness: a literature review.J Clin Med Res. 2014 Apr;6(2):75-85. doi: 10.14740/jocmr1702w. Epub 2014 Feb 6. J Clin Med Res. 2014. PMID: 24578748 Free PMC article. Review.
References
-
- Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996;279:120–127. - PubMed
-
- Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpelainen I, Haikala H. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol. 2000;32:479–491. doi: 10.1006/jmcc.1999.1093. - DOI - PubMed
-
- Simdax - Levosimendan 2.5 mg/mL injection concentrate - Data Sheet. New Zealand, New Zealand Medicines and Medical Devices Safety Authority, a Business Unit of the Ministry of Health; 2009. http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm 1-10-2010.
-
- Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999;288:316–325. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical